Abstract
The aim of this study was to investigate the role of vitamin A on RORγt and IL-17 gene expression in multiple sclerotic patients. Patients in the vitamin A group received 25,000 IU retinyl palmitate per day, while patients in the placebo group took one capsule of placebo per day for 6 months. Gene expression was measured by real-time PCR at the first and end of the study. The results of this study show that vitamin A downregulates IL-17 and RORγt gene expression. No changes in gene expression occurred in the placebo group.
Trial registration:
ClinicalTrials.gov NCT01225289.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Down-Regulation
-
Female
-
Humans
-
Interferon beta-1a
-
Interferon-beta / therapeutic use
-
Interleukin-17 / genetics
-
Interleukin-17 / metabolism*
-
Male
-
Multiple Sclerosis / drug therapy
-
Multiple Sclerosis / metabolism*
-
Nuclear Receptor Subfamily 1, Group F, Member 3 / genetics
-
Nuclear Receptor Subfamily 1, Group F, Member 3 / metabolism*
-
Transcription, Genetic / drug effects
-
Vitamin A / administration & dosage
-
Vitamin A / pharmacology*
-
Vitamins / administration & dosage
-
Vitamins / pharmacology*
Substances
-
Interleukin-17
-
Nuclear Receptor Subfamily 1, Group F, Member 3
-
RORC protein, human
-
Vitamins
-
Vitamin A
-
Interferon-beta
-
Interferon beta-1a
Associated data
-
ClinicalTrials.gov/NCT01225289